Enveric Biosciences (ENVB)
NASDAQ:ENVB
Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.71 - $17.63
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$8.17M
Enterprise Value-$3.54M
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.51
Enterprise Value/Ebitda0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Capital StructureA zero-debt profile materially reduces fixed financing costs and interest-rate exposure, which is durable for a pre-commercial biotech. Over the next 2–6 months this lowers default risk and preserves operating flexibility while the company advances IND-enabling work and seeks non-debt funding sources.
Intellectual Property ProtectionAn expanding, defensible IP position with a withdrawn PGR and issued patents strengthens barriers to entry and licensing leverage. This durable competitive advantage enhances partnering potential and de-risks future monetization paths as the company moves from preclinical to clinical development.
Advancing Lead Program Toward INDRepeated preclinical safety milestones and stated IND-enabling activities indicate systematic de-risking of EB-003. Progress toward an IND and first-in-human trials is a durable operational advance that, if sustained, shifts the company from discovery to clinical-value creation and attracts partners or non-dilutive funding.
Bears Say
No Revenue And Deep LossesPersistent negative profitability and zero operating revenue reflect a lack of commercial validation and create structural dependence on external capital. Over the medium term this constrains strategic choices, increases dilution risk, and lengthens the timeline before the company can self-fund clinical programs.
Sustained Negative Cash FlowOngoing negative operating and free cash flow, which worsened versus prior year, signals structural burn requiring repeat financing. This durable cash-generation weakness increases reliance on equity or partnerships, raising the probability of dilution and constraining execution if capital markets become less accessible.
Limited Balance-sheet FlexibilityA small equity base and modest assets limit the company's ability to absorb setbacks or raise debt without high cost. This structural balance-sheet thinness amplifies funding risk during the multi-quarter path to IND and makes strategic pivots or large partnerships harder to execute without material dilution.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.71 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $8.17M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.082.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
4.27% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
93.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---